Pharmacokinetics and Relative Bioavailability of XmAb®5871 Administered Either Intravenously or Subcutaneously

Trial Profile

Pharmacokinetics and Relative Bioavailability of XmAb®5871 Administered Either Intravenously or Subcutaneously

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Nov 2017

At a glance

  • Drugs XmAb 5871 (Primary) ; XmAb 5871 (Primary)
  • Indications Autoimmune disorders; Rheumatoid arthritis; Systemic lupus erythematosus
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Xencor
  • Most Recent Events

    • 09 May 2017 Results published in a Xencor media release.
    • 01 May 2017 Status changed from active, no longer recruiting to completed.
    • 28 Feb 2017 According to a Xencor media release, data expected in the first half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top